Follow us on Twitter
twitter icon@FreshPatents


Cancer patents

      

This page is updated frequently with new Cancer-related patent applications.

SALE: 200+ Cancer-related patent PDFs



new patent Evaluating method, evaluating apparatus, evaluating program product, evaluating system, and terminal apparatus
An evaluating method includes an evaluating step of evaluating a state of lung cancer for a subject to be evaluated using a concentration value of at least one of homoarginine, gaba, 3-me-his, adma, spermine, spermidine, cystathionine, sarcosine, aaiba, baiba, putrescine, n-acetyl-l-lys, hypotaurine, baba, and ethylglycine in blood of the subject.. .
Ajinomoto Co., Inc.


new patent Gluthatione / gold(iii) pharmaceutical composition
A method for treating cancer and gold(iii) complexes with diaminocyclohexane ligand as anticancer agents. Also described are a pharmaceutical composition incorporating the gold(iii) complexes and a method of synthesizing the gold(iii) complexes..
King Fahd University Of Petroleum And Minerals


new patent Plasma biomarker for ovarian cancer
The present invention relates to a biomarker for early stage ovarian cancer. Specifically, expression of the biomarker annexin a2 is higher in the plasma of subjects with early stage ovarian cancer.
Adelaide Research & Innovation Pty Ltd


new patent Method and kit for the detection of biliary tract cancer (as amended)
The present invention provides a method for detecting biliary tract cancer by measuring the amounts of apoa2 protein variants in a test sample with anti-apoa2 antibodies, the anti-apoa2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.. .
National Cancer Center


new patent Use of isocitrate dehydrogenase 1 as a diagnostic and prognostic biomarker and therapeutic target for lung cancers
The present invention relates to a method for diagnosing lung cancers such as non-small lung cancer in a subject by using isocitrate dehydrogenase 1 as a diagnostic biomarker. The present invention also relates to a method for predicting the prognosis of the lung cancers such as non-small lung cancer in a subject by using isocitrate dehydrogenase 1 as a prognostic biomarker.
Cancer Hospital, Chinese Academy Of Medical Sciences


new patent Method for selecting patients responsive for cancer treatments
The present invention is directed to a method of quantifying intracellular metabolite effluxes in permeabilized cancer cells for selecting cancer patients responsive for a cancer treatment, the method comprising the steps of: a) providing a sample of cancer cells taken from a patient; b) permeabilizing said cancer cells; c) incubating said permeabilized cancer cells in a reaction medium for a period of time allowing biological activity of intracellular organelles and accumulation of metabolites produced by said activity into the reaction medium in the presence of a substrate or substrates relating to a metabolite efflux or effluxes of interest, wherein said substrates used are at least glutamine and pyruvate; d) determining the quantity of metabolites relating to said metabolite efflux or effluxes of interest accumulated in the reaction medium during step c); and e) comparing the amounts of metabolites determined in step d) to equal measurements performed on control samples of the same tissue type and assessing the aggressiveness of the cancer cells or the treatment response of the cancer cells to a drug affecting a metabolic pathway or pathways relating to said metabolite efflux or effluxes of interest.. .
Mitogro OÜ


new patent Method for detecting methylation of colorectal cancer specific methylation marker gene for colorectal cancer diagnosis
The present disclosure relates to a method for detecting methylation of the bowel-cancer-specific methylation marker gpm6a (nm_201591, glycoprotein m6a) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present disclosure can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis..
Genomictree, Inc.


new patent Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer.
Genomictree, Inc.


new patent Pik3ca novel mutations detection for diagnosis of acquired cetuximab resistance in metastatic colorectal cancer patients
Disclosed is a kit for detecting drug resistance of cetuximab in the treatment of metastatic colorectal cancer. The kit comprises a substance used for detecting gene mutations in exon 19 of the pik3ca gene, and may further comprise a specification recording the following contents: if exon 19 in the pik3ca gene of a patient with metastatic colorectal cancer as a subject to be tested, who is intended to receive cetuximab treatment or is receiving cetuximab treatment and does not have drug resistance, has at least one of k944n, f930s, v955g, v955i, and k966e mutations, the subject to be tested will develop drug resistance or will be a candidate to develop drug resistance when receiving or continuing to receive cetuximab for treating metastatic colorectal cancer..
Affiliated Hospital, Academy Of Military Medical Sciences


new patent Dna aptamer binding to non-small cell lung cancer cells (h1975)
A dna aptamer comprising specifically binding to a non-small cell lung cancer cell, in which the dna aptamer has at least one nucleotide sequence selected from the sequence of seq id nos: 1 and 2; a composition for detecting lung cancer cell, comprising the dna aptamer; a kit for detecting lung cancer cell, comprising the dna aptamer; a method for detecting lung cancer comprising using the dna aptamer; a detection method comprising contacting the dna aptamer with a sample obtained from the living body selected from the group consisting of lung cells, lung tissues, blood, serum, plasma, saliva, and sputum and detecting the presence of a lung cancer cell by observing the response caused by the binding of the sample and the dna aptamer; a pharmaceutical composition for preventing metastasis of or treating lung cancer, comprising the dna aptamer, and a drug delivery system for preventing metastasis of or treating lung cancer, comprising the dna aptamer.. .

new patent

Self-aligned fibrous scaffolds for automechanoinduction of cell cultures

Self-aligned fibrous scaffolds are disclosed. The scaffolds are capable of automechanoinduction of cell cultures and methods to induce authomechanoinduction in cancer cells and stem cells are disclosed as well..
Tallinn University Of Technology

new patent

Soluble mic neutralizing monoclonal antibody for treating cancer

Described herein are compositions and methods relating to antibodies that bind soluble mic (smic), e.g. For the treatment of mic-positive cancers..
University Of Washington Through Its Center For Commercialization

new patent

Car immune cells to treat cancers

A chimeric antigen receptor (car) that binds to ceacam6, an epitope or fragment thereof, or a variant thereof.. .
National Research Council Of Canada

new patent

Dagrs: directed antigonists to cancer cell growth signals

An algorithm for “humanization” is described through which human functional equivalent(s) to viral product(s) are identified by alignment of peptides anchored at each end by matching functional motifs that are spaced equivalently distant in the two aligned peptides. The algorithm totally disregards the primary amino acid composition of the spacer, and as such separates from current computer algorithms that prioritize primary amino acid alignments.

new patent

Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins

A novel class of fluorinated derivatives of formula (i) have been prepared and found to be useful in the treatment of cancers and other disorders related mediated by bromodomain-containing proteins.. .
Trillium Therapeutics Inc.

new patent

2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof

Disclosed are a 2-(2,4,5-substituted aniline) pyrimidine derivative, a pharmaceutical composition and a use thereof. The pharmaceutical composition comprises a therapeutically effective amount of the 2-(2,4,5-substituted aniline) pyrimidine derivative, a solvate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
Changzhou Runnor Biological Technology Co., Ltd

new patent

Chemical ablation and treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue, in embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms..
Neurotronic, Inc.

new patent

Compositions and methods for in vivo imaging

This document relates to compounds useful for targeting parp1. Also provided herein are methods for using such compounds to detect and image cancer cells..
The General Hospital Corporation

new patent

Synthetic nanoparticles for delivery of immunomodulatory compounds

The present disclosure provides a synthetic nanoparticle comprising a peptide nucleic acid (pna) oligomer conjugated to a lipid, wherein the pna oligomer noncovalently complexes with an immunomodulatory compound, thereby forming a nanoparticle. The nanoparticles are useful to elicit immune responses and can be used to treat a broad range of cancers and infectious diseases..
Massachusetts Institute Of Technology

new patent

Method for mass producing natural killer cell and use of natural killer cell obtained by the method as anti-cancer agent

The present invention relates to a method for producing a large amount of natural killer cells and the use of natural killer cells obtained by the method as an anticancer agent. The use of the method of the present invention can produce fresh nk cells with high purity within a short time compared to conventional method, and can also produce cold-preserved nk cells and thawed cryopreserved nk cells, which have efficacy comparable with that of the fresh nk cells.
Korea Research Institute Of Bioscience And Biotechnology

new patent

Highly active anti-neoplastic and anti-proliferative agents

This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.. .
G1 Therapeutics, Inc.

new patent

Treatment of cancers using pi3 kinase isoform modulators

Provided herein are methods, kits, and pharmaceutical compositions that include a pi3 kinase inhibitor for treating cancers or hematologic disorders.. .
Infinity Pharmaceuticals, Inc.

new patent

Therapeutic agent for bile duct cancer

The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-n-methyl-1h-indole-1-carboxamide or a pharmacologically acceptable salt thereof.. .
Eisai R&d Management Co., Ltd.

new patent

Tryptophan is a pro-drug for infectious diseases and cancers

The innovation provides compositions and methods for treating infectious diseases and cancers, wherein said, in vitro, in higher active tdo (tryptophan 2,3-dioxygenase) sick cells that include cancer and infectious cells, tryptophan is capable of transferring into kynurenine derives to induce cells apoptosis; in vivo, tryptophan will turn into indican. Indican is capable of competing phosphorylation in the subject, competitively inhibiting process to form gtp, atp, dgtp, datp, that are essential for dna/rna synthesis; inhibiting host or invading gene amplification, or interfere with plk(polo like kinase) phosphorylation to trigger cell apoptosis.

new patent

Pharmaceutical composition for inhibiting growth of cancer stem cells, containing aldehyde inhibitor and biguanide-based compound

The present invention relates to a pharmaceutical composition for inhibiting growth of cancer stem cells, containing an aldehyde inhibitor and a biguanide-based compound. The pharmaceutical composition according to the present invention contains a combination of an aldehyde inhibitor and a biguanide-based compound, which can effectively inhibit the growth of cancer stem cells such as neurospheres and can also inhibit the proliferation, invasion and metastasis of cancer cells, thereby preventing and/or treating cancer such as brain cancer..
National Cancer Center

new patent

Falloposcope and ovarian cancer detection

A falloposcope is described, as is a method of screening a patient for fallopian tube and/or ovarian cancer with the falloposcope. The falloposcope has an optical imaging subsystem capable of performing optical and fluorescence imaging, and an optical coherence tomography (oct) channel, with a diameter of about 0.7 millimeter.
Arizona Board Of Regents On Behalf Of The University Of Arizona

new patent

Breast cancer post treatment support garment

A garment for a wearer having breasts and an under bust located directly under the breasts, and further having a torso, includes a band configured to fit at the under bust of the wearer; a cup extending from the band, the cup including an outer layer and an inner layer that is interior to the outer layer. The garment further includes an attachment component configured to removably couple an insert to the inner layer, a garment head opening, and first and second arm openings.

The protein kinase activity of phosphoglycerate kinase 1 as a target for cancer treatment and diagnosis

Compositions and methods for characterizing cancer cells by determining a marker of pgk1 activity. For example, methods are provided for predicting a patient response to a pgk1 inhibitor, a mek/erk inhibitor, an egfr inhibitor, or a pin1 inhibitor therapy.
Board Of Regents, The University Of Texas System

Materials and methods for detecting androgen receptor splice variants and uses thereof

The present disclosure relates to materials and methods for evaluating prostate cancer using binding entities (such as antibodies) that bind to the n-terminus and the c-terminus of androgen receptor. Prostate samples are histochemically labeled for the n-terminus and the c-terminus of androgen receptor, and a ratio between the binding of the n- and c-terminal antibodies is determined..
University Of Washington

Compositions, methods and kits for diagnosis of lung cancer

The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions.
Integrated Diagnostics, Inc.

Elisa detection of urine dek to predict and diagnose bladder cancer in humans

The present invention is directed to a method of detecting a dek protein in a human urine sample using an elisa assay. Methods and compositions for detection of dek using mab 260-6f9f6 (as detection antibody) and mab 16-2c9c3 (as capture antibody) in human urine are provided herein.
Medical Diagnostic Laboratories, Llc

Methods of identifying proliferation signatures for colorectal cancer

This invention relates methods and compositions for identifying colorectal cancer (crc) prognostic transcripts and groups of crc prognostic transcripts useful in determining the prognosis of cancer in a patient, particularly for gastrointestinal cancer, such as gastric or colorectal cancer. Specifically, this invention relates to crc cell culture-based methods to identify cell proliferation signatures..
Pacific Edge Limited

Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions

Disclosed herein are assays and methods for the identification of premalignant lesions, as well as methods of determining the likelihood that such premalignant lesions will progress to lung cancer. Also disclosed are methods and assays that are useful for monitoring the progression of premalignant lesions to lung cancer.
Trustees Of Boston University

Methods for the diagnosis of pancreatic cancer

The present invention relates to the diagnosis of pancreatic cancer, in particular to a salivary mi rna for use in the diagnosis of pancreatic cancer.. .
Centre Hospitalier Universitaire De Toulouse

Methods and devices for analyzing particles

Methods, devices and systems for analyzing precious samples of cells, including single cells are provided. The methods, devices, and systems in various embodiments of the invention are used to assess genomic heterogeneity, which has been recognized as a central feature of many cancers and plays a critical role in disease initiation, progression, and response to treatment.
The University Of British Columbia

Combination cancer immunotherapies with arginine depletion agents

Provided are arginine depletion agents such as adi-peg for use in combination with cancer immunotherapies, for example, immune checkpoint modulators and t-cell adoptive immunotherapies, for treating various cancers. Also provided are related methods, compositions, patient care kits, and cell cultures..
Polaris Group

T cells with increased immunosuppression resistance

This invention relates to the treatment of cancer in an individual by administration of a population of modified t cells that express a recombinant camp phosphodiesterase (pde) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified t cells and methods of producing populations of modified t cells are provided, along with pharmaceutical compositions and methods of treatment.
Adaptimmune Limited

Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward cll1 positive cells. The engineered immune cells endowed with such cars are particularly suited for immunotherapy for treating cancer, in particular leukemia..
Cellectis

Therapeutic targeting of set1b/compass pathway for treating cancers

Disclosed are methods for treating set1/compass-associated cancers characterized by expression of set1b/compass. The methods typically include administering a therapeutic amount of an inhibitor of the set1b/compass pathway and/or an agonist for a target that is negatively regulated by the set1b/compass pathway..
Northwestern University

Composition and system for separating and detecting alpha-fetoprotein variant and use thereof

Disclosed are a composition and system for separating and detecting an alpha-fetoprotein variant, comprising a separation reagent and a detection reagent; a system for separating and detecting an alpha-fetoprotein variant and a use thereof; and a kit for separating and detecting the alpha-fetoprotein variant. By means of the composition and system for separating and detecting the alpha-fetoprotein variant, and the use thereof, primary liver cancer can be indicated early on, the sensitivity is high, and the method is rapid, simple and automated..
Beijing Hotgen Biotech Co., Ltd.

Arginine-rich peptide mixture, their application thereof in cervical cancer therapy, and a process for producing same

A process for producing an arginine-rich peptide mixture and the application thereof in cervical cancer therapy is provided. The process includes the following steps: a suspension of walnut meal and egg albumin is pretreated with ultrahigh pressure, and then digested by alkaline proteinase and papain in separated steps with the ultrasonic and microwave-assisted extraction.
Nascent Peptide Biotechnology Limited

Small molecules for the treatment of primary cancer and cancer metastasis

Certain embodiments are directed to non-hydrolysable atp analogs and adenosine receptor antagonists that inhibit migration and growth of cancer cells.. .
The Board Of Regents Of The University Of Texas System

Protein tyrosine kinase modulators and methods of use

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (egfr) and alk kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various egfr mutant activity and alk kinase activity have been disclosed.
Betta Pharmaceuticals Co., Ltd.

Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer

Described herein are analogues of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogues having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as cetzole compounds, are useful to treat non-small cell lung cancer and other forms of cancer.
The University Of Toledo

5-methoxytryptophan and its derivatives and uses thereof

Wherein r1, r2, r3, r4, r5, and n are defined in the specification. In addition, the present invention also provides novel used of the 5-methoxytryptophan and its derivatives for treating inflammatory-related disease and cancers..

Column-based device and retrieval of rare cells based on size, and uses thereof

A column-based device and method for retrieving cells of interest were enclosed. The said device comprises a column comprising (i) an inner wall defining an inner chamber with inlet and outlet openings, (ii) a perforated plug disposed adjacent to the outlet opening, (iii) a sleeve insert with a channel and disposed within the chamber and adjacent to the perforated plug, and (iv) a filtering means housed within sleeve insert sandwiched between two sealing means.
Agency For Science, Technology And Research

Methods and compositions for increasing susceptibility to radiation treatment by inhibiting suppression of numerical chromosomal instability of cancer cells

Disclosed is a method for increasing susceptibility of cancer cells to ionizing radiation by delivering to the cells a radiosensitizing agent that has one of the following properties: (a) it perturbs the process of chromosome segregation thereby increasing chromosome missegregation; or (b) it is an inhibitor of an agent that promotes faithful chromosome segregation induces numeric chromosome instability in said cells and this instability is induced substantially simultaneously with or closely prior to or closely after irradiating the cells. Examples of such radiosensitizing agent include inhibitors of one or more of the following: kif2b, mcak, mps1, eg5/kinesin-5 5, polo-like kinase 4, mcak, bub1 and hec1.
The Trustees Of Dartmouth College

Synchronizing tumor cells to the g2/m phase using ttfields combined with taxane or other anti-microtubule agents

cancer cells can be synchronized to the g2/m phase by delivering an anti-microtubule agent (e.g., paclitaxel or another taxane) to the cancer cells, and applying an alternating electric field with a frequency between 100 and 500 khz to the cancer cells, wherein at least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. This synchronization can be taken advantage of by treating the cancer cells with radiation therapy after the combined action of the delivering step and the applying step has increased a proportion of cancer cells that are in the g2/m phase.
Novocure Limited

Autologous tumor vaccines and methods

Autologous anti-cancer vaccines and methods of manufacture and treatment are provided, including expansion of individual patient-derived tumor cells in an immune-compromised animal(s) to attain, quantitatively and qualitatively, sufficient material for efficacious vaccine production and utilization, to elicit an immune response against micrometastases and/or recurrence in the individual patient following tumor excision.. .
Vaccinogen, Inc.

Use of genetically engineered strain vnp20009-m in preventing and treating cancer metastasis

The present disclosure provides uses of genetically engineered attenuated salmonella typhimurium strain vnp20009-m in preventing and treating cancer metastasis. The genetically engineered strain vnp20009-m is targeted to cancer cells and has a significant effect of inhibiting metastasis and growth.
Nanjing Sinogen Biotech & Pharmaceutical Inc.

Preparation the albumin peptide combination and the action of inhibiting the proliferation of cancer cells thereof

The present invention discloses a preparation method of an albumin peptide combination and the action of inhibiting the proliferation of cancer cells thereof, the preparation steps comprise: mixing albumin and water in proportion, heating, adjusting ph, adding alkaline protease to perform enzymatic hydrolysis, deactivating, filtrating; mixing coix seed and water in proportion, decocting to extract, filtrating, adding certain proportional of water to filter residue, continue decocting to extract, collecting filtrates, determining solid matter content respectively, mixing two solutions, concentrating, spray drying, and obtaining an albumin peptide combination having the action of inhibiting the proliferation of cancer cells. The present invention found that, as compared with using coix seed individually, the effect of inhibiting the proliferation of cancer cells of albumin peptide combination is stronger, and process is simpler..
Nascent Peptide Biotechnology Limited

Id4 protein restores wild type p53 activity

A compound and method for treating cancer, in particular prostate cancer. Id4 reverts mutant p53 activity to its wild type physiological status and activity.
Clark Atlanta University

Methods for enhancing efficacy of therapeutic immune cells

The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—car) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule ci for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof..
National University Of Singapore

Platinum compounds, compositions, and uses thereof

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (iv) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof..
Placon Therapeutics, Inc.

Combination methods for treating cancers

Or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy.

Methods for treating pancreatic cancer using combination therapies

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (mm-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (mm-398) is co-administered with 5-fluorouracil and leucovorin..
Ipsen Biopharm Ltd.

Antihistamine for use in treatment of breast cancer

Disclosed herein is desloratadine or ebastin for use in treatment of a patient diagnosed with breast cancer. Also disclosed is desloratadine or ebastin for use in treatment of a patient diagnosed with a cancer type susceptible to immunotherapy..
Belina Pharma Ab

2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof

The present invention relates to the technical field of medicinal chemistry, and in particular discloses a 2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof. The compound and pharmaceutically acceptable salt, isomer, racemate, prodrug, co-crystallized complex, hydrate, and solvate thereof can effectively inhibit the bet bromodomain receptor, and can be used for preparing a medicine for treating cancers, cell proliferative disorders, inflammatory diseases, and autoimmune disorders, sepsis, and viral infections..
Guangzhou Institutes Of Biomediciene And Health, Chinese Academy Of Sciences

Use of short chain fatty acids in cancer prevention

The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids.
Temple University-of The Commonwealth System Of Higher Education

Method of treating colorectal cancers using a pkc inhibitor

The subject invention pertains to methods of treating colorectal cancer by administering an atypical pkc inhibitor. The inhibitors of apkc useful in the methods of the instant invention include acpd, ica-1, dnda and ζ-stat.
University Of South Florida

Systems and methods for response prediction to chemotherapy in high grade bladder cancer

Contemplated systems and methods allow for prediction of chemotherapy outcome for patients diagnosed with high-grade bladder cancer. In particularly preferred aspects, the prediction is performed using a model based on machine learning wherein the model has a minimum predetermined accuracy gain and wherein a thusly identified model provides the identity and weight factors for omics data used in the outcome prediction..
Nantomics, Llc

Therapeutic use for alpha1 proteinase inhibitor in hematopoiesis

A previously unrecognized fundamental property of α1pi is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified α1pi's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with hiv-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system.
The Institute For Human Genetics And Biochemistry

Detection of nucleic acids from multiple types of human papillomavirus

Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (hpv) associated with cervical cancer. Methods for detecting multiple hpv types in biological specimens by amplifying hpv nucleic acid sequences in vitro and detecting the amplified products are disclosed..
Gen-probe Incorporated

Mirna-based predictive models for diagnosis and prognosis of prostate cancer

The lack of clear predictors of prostate cancer progression leads to subjective decision-making regarding courses of treatment. The identification of new biomarkers that are predictive of recurrence after radical prostatectomy would advance the field of prostate cancer treatment.
University Of Freiburg

Multigene prognostic assay for lung cancer

The present invention provides methods for providing a prognosis for lung adenocarcinoma, using a panel of eight molecular markers that are differentially expressed in lung adenocarcinoma.. .
The Regents Of The University Of California

Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer

Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulales fzd2. The antibody may specifically bind fzd2, and may promote internalization of the fzd2 receptor by the cancer cells and/or prevent ligand binding to fzd2.
President And Fellows Of Harvard College

Methods of increasing delivery of anti-cancer agents to targets

The present invention provides compositions and methods for increasing the permeability of a stroma around a neoplasm, and particularly to cancer cells associated with solid tumors. In one embodiment, combining a therapeutic ige antibody with an anti-cancer agent in accordance with the invention increases the delivery of the anticancer agent to the site of, for example, a solid tumor in a subject.
Oncoquest, Inc.

Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof

The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (il1rap) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘can04’ to human il1rap. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of il-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma..
Cantargia Ab

Anti-cxcr4 antibodies and antibody-drug conjugates

The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (cxcr4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies.
Pfizer Inc.

Short peptide-based therapeutic agent and medicinal composition including the same for inhibiting activities of cancer cells

The present invention relates to a short peptide-based therapeutic agent and a medicinal composition including the same for inhibiting activities of cancer cells, which includes at least one short peptide listed as seq id nos: 1 and 2, either of which is unglycosylated and has no more than 40 amino acid residues, thereby specifically reducing or inhibiting activities of cancer cells such as the cancer cell proliferation, cancer stemness, cell migration, cancer cell invasion, metastasis or drug resistance.. .
National Cheng Kung University

Multi-level specific targeting of cancer cells

A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an il-13rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described..
Wake Forest University Health Sciences

Hydrocarbon-stapled polypeptides for enhancement of endosome-lysosomal degradation

The present invention relates to a beclin1-uvrag complex structure which reveals a tightly packed coiled coil assembly with beclin 1 and uvrag residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for uvrag-dependent egfr degradation but less critical for autophagy.
The Hong Kong Polytechnic University

Benzocyclooctene-based and indene-based anticancer agents

Benzocyclooctene (fused 6,8 ring system) analogues and corresponding indene (fused 6,5 ring system) analogues function as inhibitors of tubulin polymerization. The compounds are useful as anticancer agents in a new therapeutic approach for cancer treatment utilizing small-molecule inhibitors of tubulin polymerization that also act as vascular disrupting agents (vdas)..
Baylor University

Tricyclic heterocycles as anticancer agents

In which het is an aromatic heterocyclic ring and y is a point of attachment of various side chains and rings. An example of such a compound is 4-chloro-n-(3-(10,11-dihydro-5h-benzo[b]pyrido[2,3-f]azepin-5-yl)propyl)benzenesulfonamide:.

Treatment of cancers using pi3 kinase isoform modulators

Provided herein are methods, kits, and pharmaceutical compositions that include a pi3 kinase inhibitor for treating cancers or hematologic disorders.. .
Infinity Pharmaceuticals, Inc.

Processes for the preparation of a diarylthiohydantoin compound

Disclosed are processes and intermediates for the preparation of compound (x), which is currently being investigated for the treatment of prostate cancer.. .
Aragon Pharmaceuticals, Inc.

Method and device for treating cancer

A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions.

Agents for use in the detection of nuclease activity

The present invention relates to the field of diagnostics and, more in particular, to mri activatable contrast agents and compositions thereof for the detection of nuclease activity, wherein said nuclease activity is caused by microbial infection or by nuclease activity related to cancer, particularly colon cancer or pancreatic cancer. Activatable contrast agents for mri have been developed, wherein the oligonucleotide is flanked by a paramagnetic and a superparamagnetic agent, and thus providing magnetic quenching.

Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies

The invention provides compositions and methods for treating cea-positive cancers. The method comprising administering a pd-1 axis binding antagonist and a bispecific antibody that targets cea and cd3..
Hoffmann-la Roche Inc.

Antigen presenting cell targeted cancer vaccines

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-cd40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-cd40 antibody or fragments thereof, including humanized antibodies..
Bbaylor Research Institute

Imp-3 epitope peptides for th1 cells and vaccines containing the same

Isolated imp-3-derived epitope peptides having th1 cell inducibility are disclosed herein. In preferred embodiments, such a peptide of the present invention can promiscuously bind to mhc class ii molecules and induce imp-3-specific cytotoxic t lymphocytes (ctls) in addition to th1 cells.
Oncotherapy Science, Inc.

Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from an anti-hsp70 monoclonal antibody, conferring specific immunity against hsp70 positive cells. The engineered immune cells endowed with such cars are particularly suited for treating in particular leukemia..
Cellectis

Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof

The invention provides compositions including stabilized multilamellar lipid vesicles having crosslinked lipid bilayers (referred to herein as interbilayer-crosslinked multilamellar vesicles or icmv) and including an alk variant, pharmaceutical compositions containing vesicles (e.g., icmv) including an alk variant, and methods of treatment using such compositions. The invention provides compositions including stabilized multilamellar lipid vesicles with crosslinked lipid bilayers (e.g., an interbilayer-crosslinked multilamellar vesicle or icmv) containing an anaplastic lymphoma kinase (alk) variant as an antigen that is associated with solid tumor cancers..
Vedantra Pharmaceuticals, Inc.

Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing cldn18.2, including cancer diseases such as pancreatic cancer and metastases thereof.. .
Tron-translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg - Unive

Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer.
Immatics Biotechnologies Gmbh

Mesalamine for the treatment of cancer

Methods of treating renal cancer, including renal cell carcinoma, using mesalamine are disclosed herein. Mesalamine can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation..
Cipla Limited

High molecular weight polysaccharide that binds and inhibits virus

This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging.
World Force Technologies, Llc

Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life

Inoculation of atm-deficient mice with probiotic microorganisms, such as l. Johnsonii, changed immune parameters, decreased a marker of dna damage and increased the lifespan of the mice.
The Regents Of The University Of California

Macrophages eat cancer cells using their own calreticulin as a guide

Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (prcr), the methods comprising increasing prcr by contacting a phagocytic cell with a toll-like receptor (tlr) agonist; or down-regulating prcr by contacting a phagocytic cell with an inhibitor of bruton's tyrosine kinase (btk).
The Board Of Trustees Of The Leland Stanford Junior University

Medicinal composition for treating urinary tract infection (uti)

Provided is a pharmaceutical composition for use in a method of preventing or treating a urinary tract infection (uti), chronic cystitis, overactive bladder, partial bladder obstruction or urethritis, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, where in said method said composition is administered intraurethrally, intravesically, intraureterally and/or intrarenally, as well as a pharmaceutical composition for use in a method of preventing or treating bladder cancer, where in said method said composition is administered intravesically, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, wherein said tannins are bound to an anti-cancer agent and/or liposomes containing an anti-cancer agent, together with compositions related thereto.. .
Synesis Llc

Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype

In alternative embodiments, provided are compositions and methods for treating, enhancing the drug sensitivity of, and preventing the formation of cancer stems cells, including preventing or slowing the development or generation of a beta-3 (β3)-expressing, or integrin β3 (itg-b3)-expressing cancer or tumor cells. In alternative embodiments, provided are methods using histone acetyl transferase inhibitors and/or histone methyl transferase inhibitors to determine therapeutic values in cancer cells that induce an integrin β3 (itgb3) polypeptide expression.
The Regents Of The University Of California

Therapeutic target for the treatment of cancers and related therapies and methods

Disclosed herein are compositions and methods for treating or preventing certain cancers in a subject. In certain embodiments such compositions and methods generally relate to the use of g-coupled protein receptor 40 (gpr40) agonists to inhibit the growth or induce apoptosis of certain cancer cells.
The Children's Medical Center Corporation

Pharmaceutical compositions for colon-specific delivery

Disclosed are pharmaceutical particulates which release a pharmaceutical compound into the colon following oral administration. A particulate comprises a core comprising a pharmaceutical compound, an inner coating surrounding the core, wherein the inner coating comprises a pharmaceutically acceptable polysaccharide that is susceptible to enzymatic digestion by one or more enzymes present colonic microflora, and an outer coating surrounding the inner coating, wherein the outer coating comprises a polymer which is stable at upper gastrointestinal ph but can dissolve at ph>6.
Gateway Pharmaceutical Llc

Thermography-based breast cancer screening using a measure of symmetry

What is disclosed is a system and method for breast cancer screening which determines whether hot spots, as seen in a thermal image of both breasts, can be classified as possibly malignant based on a measure of symmetry. A thermographic image of both breasts of a patient is received and analyzed to determine whether there exists, in each of a left breast and a right breast, a hot spot comprising a patch of pixels with an elevated temperature with respect to surrounding tissue.
Niramai Health Analytix Pvt. Ltd.

Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient.
Applied Proteomics, Inc.

Method for the prognosis and treatment of cancer metastasis

The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, er+ breast cancer (including luminal a and b) which comprises determining if the c-maf gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-maf gene expression level, amplification or translocation.
Institució Catalana De Recerca I Estudis Avancats

Devices and methods for detection and quantification of immunological proteins, pathogenic and microbial agents and cells

The present invention provides a method and microfluidic immunoassay pscreen™ device for detecting and quantifying the concentration of an analyte in a liquid sample by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, rna, rna fragments, functionalized magnetic micro-beads specific to cd4+, cd8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays..
Carnegie Mellon University

Dynamic monitoring of receptor tyrosine kinase (rtk) activity and pathways in living cells using real-time microelectronic cell sensing technology

A method of identifying a potential therapeutic compound that affects a receptor tyrosine kinase (rtk) pathway in cancer cells, which includes: providing a device capable of measuring cell-substrate impedance; culturing cancer cells in serum-free media in at least two wells of the device; adding to a first well a proposed therapeutic compound that affects a rtk pathway and a rtk stimulating factor for the rtk pathway to form a test well, and adding to another well the rtk stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells and optionally determining cell indices from the monitored cell-substrate impedance; and determining a difference in impedance or optionally cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the rtk pathway within the cancer cells.. .
Acea Biosciences, Inc.

Monohydroxyphenyl metabolite urine detection reagent and preparation method thereof

A reagent for detection of urine monophenolic metabolites and a method for preparing the reagent are disclosed, in which the monophenolic metabolites, for example, tyrosine, p-hydroxyphenyl alanine, tryptophan and 5-hydroxyindoleacetic acid can serve as tumor markers. The reagent for detection of urine monophenolic metabolites is an aqueous solution containing nitric acid, sulfuric acid, mercuric sulfate, mercurous nitrate, nickel nitrate, phosphomolybdic acid and cobalt sulfate.
Jiangsu Dongbo Bio-pharmaceutical Co., Ltd.

Rapid quantitative detection of single nucleotide polymorphisms or somatic variants and methods to identify malignant neoplasms

Provided are systems, kits, and methods for the quantitative detection of single nucleotide polymorphisms or variants to identify malignant neoplasms. The methods include use of modified oligonucleotide blockers with peptide nucleic acid backbones that hybridize to and block logarithmic amplification of the wild-type alleles of a target, and incorporation of locked nucleic acids into probes that are complementary to a mutant allele of the target sequence to increase specificity.
The General Hospital Corporation

New markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chemotherapy

The inventors have identified several proteases and a protease inhibitor that are overexpressed in ovarian cancer tumors. They have developed monoclonal antibodies against the proteins and shown that they can be detected in serum and the levels of the proteins in serum fluctuate during cancer treatment.
Bioventures, Llc

Therapeutic compositions for breast cancer containing protein kinase d1 inhibitor

A method of inhibiting the growth of cancer stem cells, including administering an effective amount of a protein kinase d1 expression or activity inhibitor as an active ingredient to a subject having cancer is provided. Further, a method of treating cancer, including administering an effective amount of a protein kinase d1 expression or activity inhibitor, and antitumor agent as active ingredients to a subject having cancer is provided.
Sookmyung Women's University Industry Academic Cooperation Foundation

Inhibin as targetable regulators of angiogenesis

Contact of endothelial cells with inhibitors of inhibin and/or the alpha subunit of inhibin can be utilized to modify the activity of endothelial cell expression products including smad 1/5. Methods can also include inhibiting alk1 and/or endoglin as components of inhibin-activated pathway of smad 1/5 signaling.
University Of South Carolina

Micrornas sensitize cancers to therapy

The present invention concerns methods and compositions regarding one or more micrornas or variants thereof that are provided to an individual for a variety of medical treatments, including sensitization to cancer therapy or prevention of a cancer to become sensitized to a cancer therapy. In specific embodiments, the micrornas include mir-520a (including at least mir-520a-3p and mir-520-5p), mir-520g, mir-520h, and functional variants thereof.
University Of Houston

Microrna combinations for anti-cancer therapeutics

Described herein are methods and compositions of combinations of micrornas that enhance the sensitivity of cancer cells to chemotherapeutic agents or reduce proliferation of cancer cells. Also described herein are methods for the identification of combinations of micrornas that result in desired effects..
Massachusetts Institute Of Technology

Predictive marker for topoisomerase i inhibitors

The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase i (topo i) inhibitors in the treatment of cancers.
Boston Medical Center Corporation

Pro-apoptotic anti-ng2/cspg4 antibodies and their uses for disease therapy

The present invention relates to an antibody capable of binding with high-affinity and high selectivity to the ectodomain of the transmembrane proteoglycan (pg) ng2/cspg4, preferably to discrete isoforms of said pg, preferably isoforms that may be generated by alternative splicing, and/or coding single nucleotide polymorphisms, and/or post-transcriptional and/or post-translational modifications. The invention further relates to an anti-ng2/cspg4 antibody possessing the ability to uniquely induce programmed cell death, exhibited as both canonical caspase-dependent apoptosis and authophagy, in ng2/cspg4-expressing cancer cells.
Universita' Degli Studi Di Parma

Compositions and methods for cancer immunotherapy

The present invention includes, among other things, β-1,6-glucan linked to an antibody directed to a cell present in a tumor microenvironment. T regulatory cells can be one type of cell present in the tumor microenvironment.
Immunexcite, Inc.

Novel tricyclic compounds as inhibitors of mutant idh enzymes

The present invention is directed to tricyclic compounds of formula (i) which are inhibitors of one or more mutant idh enzymes: (i). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant idh enzymes are involved.
Merck Sharp & Dohme Corp.

Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

And w, z, xy, ry1 ry2 and ry3 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers..

Device and methods for broadbeam and microbeam chemo-radiosurgery combined with its tumor exosome apheresis

Surgery, chemotherapy and broadbeam and microbeam radiosurgery releases billions of abscopal metastasis causing, tumor specific plasma soluble proteins, cell membranes, apoptotic bodies, dna and rnas, exosomes like telomere-telomerase, atm-atm kinase and others. They and adaptive resistance to chemo-radiosurgery, paraneoplastic and non-paraneoplastic diseases causing immune complexes are removed by pulse flow combined continuous flow ultracentrifugation apheresis and immune affinity chromatography.

Treatment or prophylaxis of proliferative conditions

The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochromne p450 1b1 (cyp1b1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients.
University Court Of The University Of Dundee

Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment

This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-pd-1 antibody and an anti-cd27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof..
Celldex Therapeutics, Inc.

Tissue targeted antigenic activation of the immune response to treat cancers

The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.. .
Qu Biologics Inc.

Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors

The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor growth, migration, invasion or a combination and (2) improve subject survival relative to a control. The described invention also relates to a method of treating a subject with a tumor, the method comprising: (1) providing a pharmaceutical composition; and (2) administering the pharmaceutical composition, wherein the composition comprises a therapeutically effective amount of a therapeutic agent which is effective to reduce tumor growth, migration, invasion or a combination.
Hyperstem, Sa

Protein interfaces

The present disclosure provides methods to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds can be used to sensitize resistant cancer cells or decrease the proliferation of cells.
Synthex, Inc.

Stat3 and erk signal pathway inhibitor and use thereof

The present invention relates to a chemical and pharmaceutical technology, and in particular to a stat3 and erk signal pathway inhibitor and a use thereof. The present invention provides a stat3 and erk signal pathway inhibitor.
Beijing University Of Agriculture

Methods and compositions for treating c-met associated cancers

The present invention provides the use of a fungal immunomodulatory protein (fip) in manufacturing a medicament for inhibiting hepatocyte growth factor receptor (hgfr) activity in a cell, and for treating hgfr-associated cancer.. .
Yeastern Biotech Co., Ltd

Cancer immunotherapy

Methods of providing populations of nkt and/or γδ t cells, and their use, e.g., in therapies such as cancer immunotherapy.. .
University Of Massachusetts

Par-4 agonists for the treatment of cancer

Disclosed herein are methods of treating cancers by administration of a par-4 agonist.. .
Cipla Limited

Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (mm-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (mm-398) is co-administered with 5-fluorouracil and leucovorin..
Ipsen Biopharm Ltd.

Method of treating pancreatic cancer

The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.. .
Chemocentryx, Inc.

Ar+ breast cancer treatment methods

A method for treating ar+ breast cancer in a subject comprising administering to the subject an ar agonist (e.g., sarms such as rad140), or in combination with one or more therapeutic agents selected from the group consisting of cdk4/6 inhibitors, m-tor inhibitors, pi3k inhibitors, parp inhibitors, bcl-2 inhibitors, and mcl-1 inhibitors.. .
Radius Health, Inc.

Double targeted constructs to affect tumor kill

Or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer..

Selective androgen receptor degrader (sard) ligands and methods of use thereof

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (sard) compounds including heterocyclic anilide rings and their synthetic precursors, r-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, kennedy's disease, amyotrophic lateral sclerosis (als), abdominal aortic aneurysm (aaa), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (ar-fl) including pathogenic or resistance mutations, ar-splice variants (ar-sv), and pathogenic polyglutamine (polyq) polymorphisms of ar in a subject.. .
University Of Tennessee Research Foundation

Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same

The invention provides methods of inhibiting the development or progression of a thioesterase deficiency disorder in a mammal by the administration of a compound that functionally mimics the enzymatic activity of all thioesterases in mammals. Such thioesterase deficiency disorders include cancers and adult- or infant-neuronal ceroid lipofuscinoses (ncls).
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services

Biomarker kit for metastatic breast cancer prognosis and uses thereof

Provided herein are kits for detecting and quantifying the level of a metastatic cancer biomarker(s) in a patient. The kits may contain a detection and quantifying means, such as, biomarker specific antibodies.
University Of Maryland, Baltimore

Plasma autoantibody biomarkers for basal like breast cancer

cancer patients make antibodies to tumor-derived proteins that are potential biomarkers for early detection. Twenty-eight antigens have been identified as potential biomarkers for the early detection of basal-like breast cancer (tables 1, 2).
National Institutes Of Health

Methods for breast cancer treatment

Disclosed herein are methods for treating subjects with breast cancer, comprising determining a therapeutic regimen for cancer by measuring the level (amount) of proteins of one or more biomarkers. Also disclosed are methods of predicting or assessing therapeutic outcome for subject..
George Mason University

Biomarkers and targets for cancer immunotherapy

Provided herein are predictive biomarker signatures that identify patients as likely to benefit from til therapy. Also provided are tumor immunotherapy resistance pathways that may be targets of combination therapies to enhance til therapy..
Board Of Regents, The University Of Texas System

Compositions and methods relating to proliferative disorders

Methods and compositions for drug discovery, analysis and treatment of a proliferative disorder characterized by abnormal cells in a mammalian subject are provided according to aspects of the present invention which include administering a pharmaceutically effective amount of a combination of: a cytotoxic agent, a set agonist and a set ribosome antagonist. Methods and compositions according aspect of the present invention incorporate agents effective to regulate and/or affect selective translation in a cell characterized by abnormal proliferation, such as a cancer cell, thereby promoting death of the cell..
Wayne State University

Use of methylation sites in y chromosome as prostate cancer diagnosis marker

Disclosed is a use of methylation sites as a disease diagnosis marker, in particular relating to a use of methylation sites in a y chromosome as a prostate cancer diagnosis marker. More particularly, the method and criterion for screening methylation sites in chromosomes associated with a disease are established in the present invention, and using prostate cancer as an example, six methylation sites in the y chromosome associated with the prostate cancer diagnosis are screened out.
Beijing Institute Of Genomics, Chinese Academy Of Sciences

Novel rna-biomarker signature for diagnosis of prostate cancer

The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer.
Fraunhofer-gesellschaft Zur FÖrderung Der Angewandten Forschung E.v.

Consensus coding sequences of human breast and colorectal cancers

Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency.
The Johns Hopkins University

Carcinoma diagnosis and treatment based on odc1 genotype

The present invention provides methods and kits a) for preventing and/or treating cancer (e.g., colorectal cancer, neuroblastoma) that is linked, in part, to high levels of odc activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patient's whose cancer is linked, in part, to high levels of odc activity and increased cellular polyamine contents, and c) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or snp at positions +263 and/or +316 of the odc1 gene as well as cancer treatment methods, in each case, which include the determination of the odc1 genotype at the +263 and/or +316 positions, as a means to guide treatment selection.. .
Arizona Board Of Regent On Behalf Of The University Of Arizona

Nras related cancer therapy

The present invention encompasses the recognition that identification of alternative means to block ras oncogenic signaling may be required for developing novel cancer therapies. Among other things, the present invention encompasses the recognition that targeting ras palmitoylation can achieve effective therapy for ras-related cancers.
Brandeis University

Methods and materials for treating cancer

This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an scd1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccrcc)) or to increase the efficacy of a renal cell carcinoma treatment are provided.
Mayo Foundation For Medical Education And Research

Methods and compositions for selectively eliminating cells of interest

The present disclosure provides novel compositions and methods suitable for specifically eliminating target cells (e.g., cancer cells) without affecting non-target cells (e.g., non-cancer cells). For example, cr-ispr system and the compositions of the present disclosure can be employed to specifically introduce a suicidal gene into a cancer cell in the loci of a cancer-specific target sequence, which as a result of chromosomal re-arrangement or translocation in a cancer cell presents a cancer specific sequence for a guide rna and cas to be recognized and such sequence is absent in a non-cancer cell.

Polymers for inducing 3d spheroid formation of biological cells

The present invention provides the use of selected thermogelling polymers for the purpose of growing tumor spheroids. The invention provides a thermogelling platform comprising a synthetic polymer which, when seeded with cancer cells, induces the cells to grow into a natural spheroidal pattern forming a tumor spheroid.
Akina, Inc.

Novel sustained release polymer

A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit.
Tolmar Therapeutics, Inc.

Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

The present invention relates generally to the membrane transporter napi2b (slc34a2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The slc34a2 epitope peptide encompassing amino acids 312-340 of slc34a2 has been identified as an ovarian cancer epitope using the monoclonal antibody mx35.

Tem-1 diagnostic antibodies

Described herein are anybodies, and antigen-binding fragments thereof, that are specific for tumor endothelial marker 1 (tem-1), related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits.
Morphotek, Inc.

Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof

The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human b7-h3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized b7-h3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers..
Macrogenics, Inc.

Pan-elr+ cxc chemokine antibodies

Antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer..
Eli Lilly And Company

Novel compounds for the treatment of cancer

The technology provided herein relates to novel isolated polypeptides and peptides having a growth inhibitory effect on human cancer cells. Nucleic acid molecules encoding said polypeptides/peptides, vectors, host cells containing the nucleic acids and methods for preparation and producing said polypeptides/peptides.
Rheinisch-westfaelische Technische Hochschule Aachen

Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Novel synthetic biology-based adcc technologies are provided that enhance or enable adcc responses, for example, through a rationally-designed soluble universal adcc enhancer protein (suaep) where a high-affinity cd3-binding domain is fused to a high-affinity fc-binding domain. The suaep technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable..
1globe Biomedical Co., Ltd.

Colon and pancreas cancer peptidomimetics

The invention relates to a peptidomimetic of an npc-1 epitope on the muc5ac protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the npc-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods..
Precision Biologics, Inc.

Gpc3 epitope peptides for th1 cells and vaccines containing the same

Isolated gpc3-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.

Novel tricyclic compounds as inhibitors of mutant idh enzymes

The present invention is directed to tricyclic compounds of formula (i) which are inhibitors of one or more mutant idh enzymes (i); wherein a is —c(r1)═ or —n═; and x is selected from the group consisting of: (ii-i), and (ii-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant idh enzymes are involved.
Merck Sharp & Dohme Corp.

Substituted 2-anilinopyrimidine derivatives as egfr modulators

This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (egfrs), including but not limited to a variety of cancers.. .
Beta Pharma (shanghai) Co., Ltd.

Immuno-therapy for cancer treatment using iron oxide nanoparticles

An immuno-therapy for treatment of a tumor is provided. An effective dose of a composition containing a low dose of superparamagnetic iron oxide nanoparticle is administered to a tumor.
The Board Of Trustees Of The Leland Stanford Junior University

Compositions and methods for the depletion of cd117+ cells

The invention provides compositions and methods useful for the depletion of cd117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of cd117+ cells in a patient, such as a human.
Magenta Therapeutics, Inc.

Drug delivery conjugates containing unnatural amino acids and methods for using

Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids that are useful for treating cancers and inflammatory diseases..
Endocyte, Inc.

Cs1 targeted chimeric antigen receptor-modified t cells

Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing cs1 are described.. .
City Of Hope

Method of preventing or reducing the progression of prostate cancer

The embodiments include methods of preventing or reducing the progression of prostate cancer in mammals susceptible to developing prostate cancer, and to methods of reducing the incidence of clinically detected prostate cancer, using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof..
Nymox Corporation

Cortexolone 17alpha-benzoate for use in the treatment of tumours

The present invention provides certain cortexolone derivatives of formula (i), and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (i) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products..
Cosmo Technologies Ltd.

Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors

The invention relates to methods for preventing cancer in a kras-variant subject which include administering to the kras-variant subject an amount of estrogen effective to reduce the risk of developing cancer. In another aspect, the invention further relates to methods for treating cancer in a kras-variant subject, which include gradually decreasing estrogen exposure in the kras-variant subject to reduce the risk of aggressive tumor growth.
Mira Dx, Inc.

Bromodomain inhibitor as adjuvant in cancer immunotherapy

Inhibition of bromodomain proteins in antigen presenting cells is shown herein to be more inflammatory, to display lower expression of the immunosuppressive molecule pdl1, and to be capable of restoring the responsiveness of tolerant t-cells. Therefore, disclosed is a method for promoting t-cell activation during cancer immunotherapy in a subject that involves administering to a subject undergoing cancer immunotherapy a composition comprising a bromodomain inhibitor.
Dana-farber Cancer Institute, Inc.

Novel tricyclic compounds as inhibitors of mutant idh enzymes

The present invention is directed to tricyclic compounds of formula (i) which are inhibitors of one or more mutant idh enzymes: (i); wherein a is —c(r1)= or —n═; and x is selected from the group consisting of: (ii-i), (ii-ii), (i) (ii-iii), and (ii-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant idh enzymes are involved.
Merck Sharp & Dohme Corp.

Treatment of cancers using pi3 kinase isoform modulators

Provided herein are methods, kits, and pharmaceutical compositions that include a pi3 kinase inhibitor for treating cancers or hematologic disorders.. .
Infinity Pharmaceuticals, Inc.

Pharmaceutical composition comprising bicyclic nitrogen-containing aromatic heterocyclic amide compound as active ingredient

[means for solution] as a result of intensive examination for creating a pharmaceutical composition for treating various types of cancer, the inventors of the present invention confirmed that a specific bicyclic nitrogen-containing aromatic heterocyclic amide compound has the effect of inhibiting mitochondrial complex i and activating ampk, and that a pharmaceutical composition comprising the compound as an active ingredient has a treatment effect on various types of cancer in which mitochondrial complex i is involved, particularly colorectal cancer, leukemia and/or malignant lymphoma, and therefore completed the present invention.. .

Pharmaceutical composition comprising bicyclic nitrogen-containing aromatic heterocyclic amide compound as active ingredient

[means for solution] the inventors of the present invention conducted examinations on a compound having an effect of inhibiting mitochondrial complex i, and confirmed that a bicyclic nitrogen-containing aromatic heterocyclic amide compound of the present invention has the effect of inhibiting mitochondrial complex i and that this compound exhibits an anti-tumor effect on mice bearing tumors of non-small cell lung cancer-derived cells, and therefore completed the present invention.. .

Efficacy of anti-hla-dr antibody drug conjugate immu-140 (hl243-cl2a-sn-38) in hla-dr positive cancers

The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an anti-hla-dr antibody or antigen-binding antibody fragment. The immunoconjugate may be administered at a dosage of between 3 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8, 10 or 12 mg/kg.
Immunomedics, Inc.

Injectable anticancer composition for local administration containing suspension of quinine salt

Disclosed herein is an injectable anticancer composition for local administration, which contains a suspension of quinine hydrochloride. The anticancer composition for local administration according to the present invention shows an ic50 value against mkn-45 cells, which is about 10 times lower than paclitaxel, as determined by an mtt assay in vitro, suggesting that the anticancer composition has an excellent cytotoxic effect.

Selective inhibition of hdac6 and hdac8, and methods of use thereof

The present invention relates to methods of selectively modulating (for example inhibiting) the activity of histone deacetylase 6 and/or 8 (hdac6 and/or hdac8), and treating hdac6 and/or hdac8 associated diseases, including, for example, cancers, inflammatory disorders, and neurodegenerative disorders.. .
Reaction Biology Corp.

Anticancer compositions

The present invention concerns pharmaceutical formulations of arn-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (ar)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of arn-509 and hpmcas.
Aragon Pharmaceuticals, Inc.

Biflavone compound and uses thereof for treating cancers and preparing drugs

Provided in the present invention is a compound having these structure of formula i or a pharmaceutically acceptable salt thereof. Also provided in the present invention is a pharmaceutical composition containing the compound, and a use of the compound for treating cancers..
Fujian Medical University

Pharmaceutical composition for treating cancer, containing lactate metal salt

The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer metastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention inhibits the growth of cancer cells and induces the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibits the expression of factors inducing resistance against radiation exposure, while having no side effects.
Metimedi Pharmaceuticals Co., Ltd.

Fkbp52-specific androgen receptor inhibitor, mjc13, for use in treating breast cancer

Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of mjc13 to a subject in need thereof.. .
The Regents Of The University Of Colorado, A Body Corporate

2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione as a cancer therapeutic

2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione (dmdd), as well as variants, derivatives, analogs, modifications, and conjugates thereof, are identified as therapeutic agents for treating or preventing human cancers and precancerous conditions. Dmdd can be isolated from the root of averrhoa carambola l., commonly known as starfruit.
Middle Tennessee State University

Hydroxynaphthoquinone compounds for treatment of non-small cell lung cancer

A compound suitable for treating egfr-dependent non-small cell lung cancer exceptionally inhibits activity of the egfr kinase, in particular in egfr-dependent non-small cell lung cancer with intrinsic or acquired resistance against at least one egfr inhibitor. Methods for inhibiting egfr kinase activity in non-small cell lung cancer cells which harbor an abnormality in the egfr gene and for targeting cancer cells harboring an abnormality in egfr gene by contacting egfr-dependent non-small cell lung cancer cells with said compound are also provided.
Macau University Of Science And Technology

Anticancer compositions

The present invention concerns pharmaceutical formulations of arn-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (ar)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of arn-509, a poly(meth)acrylate copolymer and hpmcas.
Aragon Pharmaceuticals, Inc.

Anticancer compositions

The present invention concerns pharmaceutical formulations of arn-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (ar)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of arn-509 and a poly(meth)acrylate copolymer.
Aragon Pharmaceuticals, Inc.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cancer for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cancer with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.9285

file did exist - 13903

1 - 1 - 284